DEPAKENE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DEPAKENE (DEPAKENE).
Increases GABA concentration in the brain by inhibiting GABA transaminase and blocking voltage-gated sodium channels; also modulates histone deacetylase activity.
| Metabolism | Hepatic via glucuronidation (30-50%), beta-oxidation (40%), and CYP-mediated oxidation (including CYP2C9). |
| Excretion | Renal: <3% unchanged; primarily hepatic metabolism via glucuronidation (50%) and beta-oxidation (40%), with metabolites excreted renally. Fecal: negligible. |
| Half-life | 10-16 hours (monotherapy); 5-9 hours in patients on enzyme-inducing co-medications; prolonged in hepatic impairment (up to 30 hours) or neonates. |
| Protein binding | 90% (albumin); saturable, leading to decreased binding in uremia or hypoalbuminemia; free fraction increases at concentrations >100 mg/L. |
| Volume of Distribution | 0.1-0.4 L/kg; low Vd consistent with high protein binding and limited tissue distribution; increases with age (e.g., 0.6 L/kg in neonates). |
| Bioavailability | Oral: nearly 100% (conventional and extended-release). |
| Onset of Action | Oral: 1-4 hours (peak serum levels in 1-4 hours for conventional, 3-8 hours for enteric-coated); IV: immediate (within minutes for status epilepticus). |
| Duration of Action | Variable; dosing frequency typically twice daily (conventional) or once daily (extended-release); effective serum trough levels sustained for 12-24 hours depending on formulation. |
| Molecular Weight | 144.21 |
| Action Class | Sodium channel modulators (AED) |
Oral: Initial 15 mg/kg/day divided into 1-3 doses, increase by 5-10 mg/kg/day weekly; typical maintenance 30-60 mg/kg/day. Intravenous: Same total daily dose as oral, administered as continuous infusion or divided q6h.
| Dosage form | CAPSULE |
| Renal impairment | GFR 10-50 mL/min: Administer every 12-24 hours. GFR <10 mL/min: Administer every 24 hours with reduced dose (consider 50% reduction). Hemodialysis: Supplemental dose post-dialysis may be needed. |
| Liver impairment | Child-Pugh Class A: Use 50% of normal dose. Child-Pugh Class B: Use 25% of normal dose. Child-Pugh Class C: Contraindicated due to risk of hepatic failure. |
| Pediatric use | Children ≥10 kg: Oral/IV 15 mg/kg/day initially; increase by 5-10 mg/kg/day weekly up to 30-60 mg/kg/day divided q8h. Infants <10 kg: 15-45 mg/kg/day divided q8h. |
| Geriatric use | Start at low end of dosing range (e.g., 250 mg BID) and titrate slowly; monitor for sedation, tremor, and thrombocytopenia. Reduced clearance may require 20-40% lower doses. |
| 1st trimester | High risk of neural tube defects and other major malformations; avoid unless no alternative. |
| 2nd trimester | Ongoing risk of congenital abnormalities; consider switching if possible. |
| 3rd trimester | Risk of hemorrhagic disease in newborn due to vitamin K deficiency; maternal use may cause withdrawal symptoms in neonate. |
Clinical note
Comprehensive clinical and safety monograph for DEPAKENE (DEPAKENE).
| Placental transfer | Valproate readily crosses the placenta with maternal serum concentrations equilibrating with fetal serum. Cord blood levels are approximately 1.5 times maternal levels. |
| Breastfeeding | Depakene is excreted into breast milk in low concentrations (1-10% of maternal serum levels). Monitor infant for thrombocytopenia, hepatic dysfunction, and drowsiness. Use caution, especially in combination with other anticonvulsants. |
■ FDA Black Box Warning
Hepatotoxicity, particularly in children under 2 years of age and those with pre-existing hepatic disease; teratogenicity, including neural tube defects (e.g., spina bifida).
| Serious Effects |
Hepatic disease or significant hepatic dysfunctionUrea cycle disordersKnown hypersensitivity to valproatePregnancy in women with epilepsy unless no alternative (due to high teratogenicity)
| Precautions | Pancreatitis, thrombocytopenia, hyperammonemic encephalopathy, multi-organ hypersensitivity reactions, suicidal ideation, drowsiness, and monitoring of liver function and platelet counts. |
| Food/Dietary | Depakene should be taken with food or milk to minimize gastrointestinal irritation. Avoid alcoholic beverages as alcohol may potentiate CNS depression and increase hepatotoxicity risk. Grapefruit juice may slightly increase valproate absorption but not clinically significant; no restriction needed. No specific food interactions are documented; however, maintaining consistent dietary habits regarding fat intake is advised as high-fat meals may increase absorption of some formulations. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Valproate (DEPAKENE) is highly teratogenic. First trimester: Increased risk of neural tube defects (spina bifida, 1-2%), facial clefts, cardiac malformations, and hypospadias. Second and third trimester: Risk of neurodevelopmental disorders (e.g., autism, reduced IQ) with prenatal exposure. Fetal valproate syndrome includes characteristic facial features. Risk is dose-dependent, especially >1 g/day. |
| Fetal Monitoring | Preconception: Ensure folate supplementation (5 mg/day). First trimester: Ultrasound for neural tube defects (NTD) and fetal anatomy. Second trimester: Detailed anomaly scan, fetal echocardiogram. Throughout: Monitor maternal valproate trough concentrations (target lower effective dose). Maternal liver function tests (AST, ALT, bilirubin), complete blood count (CBC) with platelets, coagulation studies. Third trimester: Assess for fetal growth restriction. Postnatal: Monitor infant for bleeding (vitamin K prophylaxis recommended), withdrawal symptoms, and neurodevelopment. |
| Fertility Effects | Valproate may cause menstrual irregularities, anovulation, and polycystic ovary syndrome (PCOS)-like changes (e.g., hyperandrogenism, hyperinsulinemia) in women of reproductive age, potentially impairing fertility. Weight gain and metabolic disturbances may contribute. In men, reversible sperm abnormalities (reduced motility, abnormal morphology) have been reported. Effects are generally reversible upon discontinuation. |
| Clinical Pearls | Depakene (valproic acid) is a broad-spectrum antiepileptic. Monitor liver function tests (LFTs) and ammonia levels, especially in children under 2 years or with metabolic disorders. Valproate can cause hyperammonemia even with normal LFTs. Check serum levels (therapeutic range: 50-100 mcg/mL); toxicity risk increases above 100 mcg/mL. Avoid in pregnant women due to high teratogenicity (neural tube defects). Use with caution in patients with mitochondrial disease or urea cycle disorders. Administer with food to reduce GI irritation. Slow IV infusion (over 60 min) to avoid hypotension. For status epilepticus, use IV loading dose 15-20 mg/kg. Discontinue slowly to avoid withdrawal seizures. |
| Patient Advice | Take Depakene exactly as prescribed; do not stop suddenly as it may cause seizures. · Swallow tablets whole; do not crush or chew (extended-release forms). · Take with food or milk to reduce stomach upset. · Notify your doctor immediately if you experience yellowing of eyes/skin, dark urine, severe nausea/vomiting, unusual bleeding/bruising, or extreme drowsiness. · Avoid alcohol while taking this medication. · Use effective contraception; Depakene can harm an unborn baby. · Do not drive until you know how this drug affects you; may cause drowsiness or dizziness. · Regular blood tests are needed to monitor liver function and drug levels. · Report any persistent vomiting, abdominal pain, or confusion as these may indicate hyperammonemia. · Tell your dentist about Depakene use before any procedures. |